YC

Yu-chen Jenny Chen

IT Consultant at Resolve Biosciences

Yu-chen Jenny Chen has worked in the IT industry since 1999. Yu-chen Jenny began their career at ASE, Inc. as an MIS Support. Yu-chen Jenny then moved to Lucent Technology as a Technical Support Engineer. In 2000, they joined LSI as a Windows System Administrator and also worked at Lucent Technology in the same year. In 2007, they became an IT System Administrator at Innovative Silicon. Yu-chen Jenny then moved to Vendavo as a Sr. System Administrator in 2010. In 2018, they joined Minerva Networks as a System Engineer and is currently an IT Consultant at Resolve BioSciences.

Yu-chen Jenny Chen's education history includes a Master of Arts degree in Communication Management from the University of Southern California, obtained between 1997 and 1998. Prior to that, they attended Cornell University in 1996 and 1997, studying Mass Communication. Yu-chen Jenny obtained their Bachelor of Arts degree in Sociology from National Taiwan University between 1992 and 1996. In addition, they have obtained three certifications: Cert Prep: VMware Certified Associate (VCA-DBT) from Lynda.com in March 2019, AWS Certified Solution Architect Associate from Aws Certified Solutions Architect Associate Online Classroom Training in April 2019, and MCSE, CCNA, SCSA.

Location

Sunnyvale, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Resolve Biosciences

Resolve Biosciences is applying the power of Molecular Cartography™ to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company's proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The platform offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program.


Employees

51-200

Links